(Q33510256)

English

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 July 2017

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study (English)

1 reference

Europe PubMed Central

27 July 2017

multiple sclerosis

0 references

Claudio Gasperini

object named as

Claudio Gasperini

3

0 references

Valentina Tomassini

2

object named as

Valentina Tomassini

1 reference

Europe PubMed Central

27 July 2017

author name string

Emilia Sbardella

1

1 reference

Europe PubMed Central

27 July 2017

Francesca Bellomi

4

1 reference

Europe PubMed Central

27 July 2017

Luca Ausili Cefaro

5

1 reference

Europe PubMed Central

27 July 2017

Vincenzo Brescia Morra

6

1 reference

Europe PubMed Central

27 July 2017

Guido Antonelli

7

1 reference

Europe PubMed Central

27 July 2017

Carlo Pozzilli

8

1 reference

Europe PubMed Central

27 July 2017

publication date

13 October 2009

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

27 July 2017

9

1 reference

Europe PubMed Central

27 July 2017

54

1 reference

Europe PubMed Central

27 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2377-9-54

0 references

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Considerations on the development of serum antibodies to interferon-beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770509

21 June 2018

Epitope specificity of neutralizing antibodies against IFN-beta

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-54

21 January 2018

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of neutralization of interferon by antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of MRI activity before and during interferon beta-1a therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19825153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2377-9-54

1 reference

Europe PubMed Central

27 July 2017

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-9-54

9 September 2019

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33510256&oldid=1535731377"